武田与日本京都大学iPS细胞研究所（CiRA）达成10年干细胞合作

2015年4月17日讯/生物谷BIOON/--日本制药巨头武田（Takeda）近日宣布，与日本京都大学iPS细胞研究所（CiRA）达成了一项为期10年的iPS细胞研究合作，双方将联手开发诱导多能干细胞（iPSC）在多个领域的临床应用，如心脏衰竭、糖尿病、神经性疾病、肿瘤免疫治疗等。该项“武田-CiRAiPS细胞应用联合项目（T-CiRA）”旨在利用iPSC技术加速推进药物发现和细胞疗法的多个研究项目。CiRA所长山中伸弥（ShinyaYamanaka）将负责指导T-CiRA项目，武田将提供长期资金支持、科研管理建议以及提供位于日本藤泽湘南研究中心的设施。
诱导多能干细胞（iPSC）技术有望对未来的医学治疗带来突破性的变革，而且它们的应用涵盖多个领域，包括药物发现、细胞疗法、药物安全性评估等。在为期10年的合作中，武田和CiRA将在CiRA研究专家的领导下联合运营项目。此次合作有望为iPSC技术科学和应用向临床实践的推进做出显著贡献，而这需要大量的时间、精力和投资。
在为期10年的合作期，武田将为其湘南研究中心提供科研设施，提供200亿日元（约合1.38亿美元）的合作资金。同时，武田还将提供价值超过120亿日元（约合1.008亿美元）的研究支持（设施、设备、武田研究人员及各种研究服务）；包括从全球招聘的新的研究人员在内大约100名研究人员将在武田的湘南研究中心从事共同研究。此外，武田还将为合作项目提供相关的研究资产，如武田的化合物文库。
潜在的初始研究项目将包括心脏衰竭、糖尿病、神经精神病学疾病、肿瘤免疫疗法。随着合作的推进，其他项目也将纳入进来。一旦运作起来，大约有10个项目将会同期开展。
日本京都大学iPS细胞研究所（CiRA）隶属于日本京都大学，是一个专注于干细胞研究的顶级科研机构，现任所长山中伸弥是2012年诺贝尔生理学或医学奖得主，是干细胞研究领域的泰山北斗级人物。
英文原文：CiRAandTakedaEnter10-yearCollaborationoniPSCellResearch
CiRAandTakedaEnter10-yearCollaborationoniPSCellResearch
KyotoandOsaka,Japan,April17,2015–CenterforiPSCellResearchApplication(CiRA)ofKyotoUniversityandTakedaPharmaceuticalCompanyLimited(Takeda)announcedtodaythattheywillworktogethertodevelopclinicalapplicationsofinducedpluripotentstemcellsinareassuchasheartfailure,diabetesmellitus,neurologicaldisordersandcancerimmunotherapy.The“Takeda-CiRAJointProgramforiPSCellApplications”(T-CiRA)isdesignedtoexpeditemultipleresearchprojectsfordrugdiscoveryandcelltherapyusingiPScells.CiRADirectorShinyaYamanaka,aNobellaureateforhisworkoniPScells,willdirecttheProgram,whileTakedaprovideslong-termfunding,recommendationsonresearchmanagement,andfacilitiesatitsShonanResearchCenter,Fujisawa,Japan.
iPScelltechnologieshavethepotentialtobringaboutground-breakingtransformationstofuturemedicaltreatments,andtheirapplicationsspanavarietyoffields,includingdrugdiscovery,celltherapyanddrugsafetyassessments.Duringaperiodof10years,TakedaandCiRAwilljointlyrunprojectsledbyresearchexpertsinvitedfromCiRA.ThecollaborationisexpectedtomakesignificantcontributionstothescienceandapplicationofiPScelltechnologyintoclinicalpractice,whichrequiresasignificantamountoftime,effortandinvestment.
“This10-yearjointprogramwithTakeda,Japan’slargestpharmaceuticalcompany,willbecomeapowerfulenginetorealizingmedicalapplicationsusingiPScells,”saidYamanaka.“WesincerelythankTakeda’scommitmenttoiPScellresearch.Thispartnershipwillcontributetothedevelopmentofnewtherapiestocurenotonlymajordiseasesbutalsorareones.”
“IamexcitedthatwewillbeabletocollaboratewithCiRA,theworld’sleadinginstitutededicatedtopioneeringiPScellresearch,”saidChristopheWeber,President,andChiefExecutiveOfficerofTakeda.“Throughthispartnership,ourcompanywillprovidesignificantassistanceoveralongperiodtoCiRA’sresearchintoiPScelltechnologyapplications,whichisavitalpartofJapanRevitalizationStrategy.ItisourhopetodeliverinnovativetreatmentsthatmeetpatientneedsassoonaspossiblethroughthiscollaborationbetweenTakedaandCiRA.”
ThiscollaborationisalignedwiththepurposeofNationalProjectsofJapanonclinicalapplicationsofiPScelltechnologies.TakedawillprovideresearchfacilitiesatitsShonanResearchCenterandcollaborativefundingof20billionyenovera10-yearperiod.Inaddition,Takedawillprovidemorethan12billionyenworthofresearchsupport(facility,equipment,Takedaresearchersandvariousresearchservices)overthe10-yearcollaborationperiod.About100researchersincludingnewresearchersrecruitedgloballyaretobebasedatTakeda’sShonanResearchCenterengagedinjointresearch,witheachcontributingabout50researchers.Also,theaccesstospecialresearchassets,suchasTakedascompoundlibraries,willbeprovidedforthecollaboration.
Potentialinitialresearchprojectsincludeheartfailure,diabetesmellitus,neuro-psychiatricdisorders,andcancerimmunotherapy.Additionalprojectswillbeincludedasthecollaborationmovesforward.Oncesetup,around10projectswillbepursuedconcurrently.
AbouttheCenterforiPSCellResearchandApplicationatKyotoUniversity(CiRA)CiRA,the14thresearchinstituteatKyotoUniversity,wasestablishedonApril1,2010toserveastheworld’sfirstcoreinstitutededicatedtopioneeringiPScellresearch.WithDr.ShinyaYamanakaservingasDirector,theCenter’s30researchgroupsareengagedinbasicresearch,researchleadingtopreclinicalandclinicalapplications,andresearchofethicalissues,withtheoverallgoalofusingiPScellstorealizeregenerativemedicineanddrugdiscovery.AdditionalinformationaboutCiRAisavailablethroughitswebsiteatwww.cira.kyoto-u.ac.jp.
医药网新闻